Show simple item record

dc.contributor.authorSrichawla, Bahadar S
dc.contributor.authorTelles, Chloe C
dc.contributor.authorSchweitzer, Melanie
dc.contributor.authorDarwish, Bilal
dc.date.accessioned2023-09-12T17:11:26Z
dc.date.available2023-09-12T17:11:26Z
dc.date.issued2022-04-12
dc.identifier.citationSrichawla BS, Telles CC, Schweitzer M, Darwish B. Attention Deficit Hyperactivity Disorder and Substance Use Disorder: A Narrative Review. Cureus. 2022 Apr 12;14(4):e24068. doi: 10.7759/cureus.24068. PMID: 35573587; PMCID: PMC9097465.en_US
dc.identifier.issn2168-8184
dc.identifier.doi10.7759/cureus.24068en_US
dc.identifier.pmid35573587
dc.identifier.urihttp://hdl.handle.net/20.500.14038/52486
dc.description.abstractAttention deficit hyperactivity disorder (ADHD) has a growing incidence and prevalence in the United States and throughout the world, much of which is contributed to increased awareness of the condition and solidified diagnostic criteria. Substance use disorder (SUD) similarly has seen a sharp increase, particularly with the rising cases of opioid abuse. Management of ADHD is done primarily with pharmacologic therapy, often stimulants and with psychosocial interventions (i.e., exercise, meditation, peer-to-peer intervention, etc.) for adjunctive management. Management of SUD involves cessation and treatment based on the underlying drug of abuse. Many clinicians are uncomfortable treating ADHD in patients with SUD based on concerns the intervention may lead to an adverse event, including drug relapse, and the development of other psychiatric comorbidities. Concerns also arise about stimulants acting as a gateway drug in adolescents leading to the onset of SUD. Thus, in this narrative review, we aim to shed light on ADHD in relation to SUD and to provide clinical insight based on the current scientific literature on the topic. ADHD causes lesions in subcortical structures in the basal ganglia and limbic system. Treatment of ADHD with stimulants has been shown to normalize malformed neuroanatomical variations and lead to improved long-term outcomes compared to non-treatment of ADHD. Based on current scientific literature, it is recommended to treat ADHD with guideline-directed pharmacologic agents including stimulants along with non-pharmacologic interventions primarily exercise. There may be some improvement in reducing risky behavior, such as substance abuse, and may even help prevent the development of SUD.en_US
dc.language.isoenen_US
dc.relation.ispartofCureusen_US
dc.relation.urlhttps://doi.org/10.7759/cureus.24068en_US
dc.rights© Copyright 2022 Srichawla et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC- BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.en_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectaddiction psychiatryen_US
dc.subjectattention deficit hyperactivity disorder (adhd)en_US
dc.subjectdrug addictionen_US
dc.subjectmedicineen_US
dc.subjectneurologyen_US
dc.subjectneuropsychiatryen_US
dc.subjectopioids use disorderen_US
dc.subjectpsychiatryen_US
dc.subjectstimulant abuseen_US
dc.subjectsubstance use disorderen_US
dc.titleAttention Deficit Hyperactivity Disorder and Substance Use Disorder: A Narrative Reviewen_US
dc.typeJournal Articleen_US
dc.source.journaltitleCureus
dc.source.volume14
dc.source.issue4
dc.source.beginpagee24068
dc.source.endpage
dc.source.countryUnited States
dc.identifier.journalCureus
refterms.dateFOA2023-09-12T17:11:27Z
dc.contributor.departmentNeurologyen_US


Files in this item

Thumbnail
Name:
20220512-1531-1sdoyrz.pdf
Size:
249.0Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

© Copyright 2022
Srichawla et al. This is an open access
article distributed under the terms of the
Creative Commons Attribution License CC-
BY 4.0., which permits unrestricted use,
distribution, and reproduction in any
medium, provided the original author and
source are credited.
Except where otherwise noted, this item's license is described as © Copyright 2022 Srichawla et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC- BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.